GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InspireMD Inc (FRA:II2) » Definitions » Institutional Ownership

InspireMD (FRA:II2) Institutional Ownership : 0.08% (As of May. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is InspireMD Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, InspireMD's institutional ownership is 0.08%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, InspireMD's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, InspireMD's Float Percentage Of Total Shares Outstanding is 72.15%.


InspireMD Institutional Ownership Historical Data

The historical data trend for InspireMD's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InspireMD Institutional Ownership Chart

InspireMD Historical Data

The historical data trend for InspireMD can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 0.13 0.13 0.13 0.09 0.09 0.08 0.08 0.08 0.08 0.08

InspireMD Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


InspireMD (FRA:II2) Business Description

Traded in Other Exchanges
Address
4 Menorat Hamaor Street, Tel Aviv, ISR, 6744832
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries.

InspireMD (FRA:II2) Headlines

No Headlines